Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 200 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $200.400 million which missed the analyst consensus estimate of $202.484 million by 1.03 percent. This is a 2.30 percent increase over sales of $195.900 million the same period last year.